This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Adult patients with R/R DLBCL with eligible subtypes, including transformed DLBCL, were enrolled. Patients must have received ≥2 previous lines of systemic therapy, be ineligible for hematopoietic SCT ...

The utility of this pipeline was convincingly illustrated using tumor-on-chip ecosystem data. The newly developed pipeline could be used to better understand cell-cell interactions and could also be ...

skin lymphoma progresses through stages. The stage of the disease affects how it is treated and what the overall prognosis is. The stages are further categorized with a number that represents the ...

This finding advances our understanding of how blood vessels sprout new branches through cell migration. Blood vessels supply the cells in our bodies with the oxygen and nutrients they need to ...

The American Cancer Society’s most recent estimates for all types of non-Hodgkin lymphoma (NHL) in the United States for 2025 are: 80,350 new cases of NHL (45,140 in men and 35,210 in women) 19,390 ...

Their study in mice found that during periods of low energy— such as intermittent fasting—ILC2 immune cells step in to regulate blood sugar ... body states into peripheral immune functions ...

The moon is expected to turn an eerie blood-red above the skies of the U.S. in the coming months, due to a rare total lunar eclipse. Late on March 13 and in the early hours of March 14 this year ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings experienced worse outcomes than observed in trials. Higher toxicity rates ...